1868 Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer (MBC) treated with pertuzumab (P) in the first-line in a real-world setting. (September 2015) - Robert, N.; Goertz, H.P.; Asmar, L.; Tseng, W.Y.; Jiao, X.; Portera, C.; Yoo, B.; Patt, D.; Antao, V.